Literature DB >> 32042672

Predicting the likelihood of early recurrence based on mRNA sequencing of pituitary adenomas.

Xi Wang1, Dainan Zhang1,2, Shunchang Ma2, Peiliang Li1,3, Wenjianlong Zhou1, Chuanbao Zhang1,2, Wang Jia1,2.   

Abstract

BACKGROUND: There is no comprehensive and objective method existing for predicting early recurrence of pituitary adenomas (PAs). The most advanced gene sequencing technology can be applied to build a prognostic model that can effectively predict early recurrence of PAs.
METHODS: In this study, using mRNA-Seq data, the corresponding postoperative early recurrence status, and other clinical features of 107 PA samples were obtained and randomly divided into the training and validation groups. Cox regression and receiver operating characteristic (ROC) analysis accompanied by the risk score method was used to build a seven-gene prediction model.
RESULTS: Area under curve values was 0.857 in the training group, 0.936 in the validation group, and 0.848 in all patients. Patients with low-risk scores had a significantly lower probability of early postoperative recurrence compared to those acquiring high-risk scores in the training group, validation group, and all patient (P<0.0001) groups. In addition, 6 out of these 7 significant genes were highly correlated to the early recurrence of PAs.
CONCLUSIONS: This prediction model derived from mRNA-Seq data may help in identifying the early recurrence of PAs, consequently aiding in the classification of patients with PAs and the administration of the appropriate therapeutic and follow-up strategy for these patients. 2019 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Cox regression; Pituitary adenomas (PAs); early recurrence; mRNA-Seq; predicting model

Year:  2019        PMID: 32042672      PMCID: PMC6989919          DOI: 10.21037/gs.2019.11.02

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  18 in total

1.  Large and giant pituitary adenoma resection by microscopic trans-sphenoidal surgery: Surgical outcomes and complications in 123 consecutive patients.

Authors:  Mohan Karki; Jinzhang Sun; Chandra Prakash Yadav; Bing Zhao
Journal:  J Clin Neurosci       Date:  2017-08-01       Impact factor: 1.961

2.  Primer on multiple regression models for diagnostic imaging research.

Authors:  Ilana F Gareen; Constantine Gatsonis
Journal:  Radiology       Date:  2003-11       Impact factor: 11.105

3.  Nucleolin modulates the subcellular localization of GDNF-inducible zinc finger protein 1 and its roles in transcription and cell proliferation.

Authors:  Atsushi Dambara; Takatoshi Morinaga; Naoyuki Fukuda; Yoshinori Yamakawa; Takuya Kato; Atsushi Enomoto; Naoya Asai; Yoshiki Murakumo; Seiichi Matsuo; Masahide Takahashi
Journal:  Exp Cell Res       Date:  2007-07-14       Impact factor: 3.905

4.  HOXB5 induces invasion and migration through direct transcriptional up-regulation of β-catenin in human gastric carcinoma.

Authors:  Chang-Soo Hong; Oh Jeong; Zhengri Piao; Chen Guo; Mi-Ran Jung; Chan Choi; Young-Kyu Park
Journal:  Biochem J       Date:  2015-10-14       Impact factor: 3.857

Review 5.  The 2017 World Health Organization classification of tumors of the pituitary gland: a summary.

Authors:  M Beatriz S Lopes
Journal:  Acta Neuropathol       Date:  2017-08-18       Impact factor: 17.088

6.  High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.

Authors:  Carmen Criscitiello; Davide Disalvatore; Michele De Laurentiis; Lucia Gelao; Luca Fumagalli; Marzia Locatelli; Vincenzo Bagnardi; Nicole Rotmensz; Angela Esposito; Ida Minchella; Sabino De Placido; Michele Santangelo; Giuseppe Viale; Aron Goldhirsch; Giuseppe Curigliano
Journal:  Breast       Date:  2013-12-04       Impact factor: 4.380

7.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

Review 8.  Translational research in oncology--10 years of progress and future prospects.

Authors:  James H Doroshow; Shivaani Kummar
Journal:  Nat Rev Clin Oncol       Date:  2014-10-07       Impact factor: 66.675

9.  Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.

Authors:  Marco Losa; Pietro Mortini; Raffaella Barzaghi; Paolo Ribotto; Maria Rosa Terreni; Stefania Bianchi Marzoli; Sandra Pieralli; Massimo Giovanelli
Journal:  J Neurosurg       Date:  2008-03       Impact factor: 5.115

Review 10.  The 2017 WHO classification of pituitary adenoma: overview and comments.

Authors:  Naoko Inoshita; Hiroshi Nishioka
Journal:  Brain Tumor Pathol       Date:  2018-04-23       Impact factor: 3.298

View more
  3 in total

Review 1.  Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions.

Authors:  Liang Lu; Xueyan Wan; Yu Xu; Juan Chen; Kai Shu; Ting Lei
Journal:  Diagnostics (Basel)       Date:  2022-04-13

2.  Caveolin-1 regulates the expression of miR-183 and inhibits the invasion and migration of invasive pituitary adenomas by affecting early growth response 1 (EGR1)/Krueppel-like factor 5 (KLF5) interaction.

Authors:  Huan Ma; Zheying Zhang; Yang Wang; Fei Shang; Baoshun Du; Yungang Wang; Zhenguo Cheng
Journal:  Gland Surg       Date:  2020-12

3.  Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma.

Authors:  Wen Lyu; Xu Fei; Cheng Chen; Yuqun Tang
Journal:  Gland Surg       Date:  2021-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.